Prosecution Insights
Prosecution Insights
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (11%) |
| §103 only | 3 (33%) |
| §102 only | 3 (33%) |
| §112 only | 1 (11%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCLEOD, AFRICA MHAIRIE | 1 | 44.7% | +68.6% |
| SAHAND, SANA | 1 | 62.3% | +26.9% |
| HALVORSON, MARK | 1 | 48.0% | +21.6% |
| IVANOVA, SVETLANA M | 1 | 50.5% | +51.9% |
| POPA, ILEANA | 1 | 21.0% | +14.9% |
| BAUSCH, SARAE L | 1 | 29.0% | +43.8% |
| ELENISTE, PIERRE PAUL | 1 | 38.5% | +30.2% |
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +33.6% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +41.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906115 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING GLUTAMINASE INHIBITOR-SENSITIVE CANCERS | BAUSCH, SARAE L | 118d overdue |
| 19197587 | METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS | SAHAND, SANA | 32d overdue |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17776961 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ELENISTE, PIERRE PAUL | 127d overdue |
| 17906115 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING GLUTAMINASE INHIBITOR-SENSITIVE CANCERS | BAUSCH, SARAE L | 118d overdue |
| 19197587 | METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS | SAHAND, SANA | 32d overdue |
| 19355121 | OLIGONUCLEOTIDES FOR PRNP MODULATION | MCLEOD, AFRICA MHAIRIE | 9d overdue |
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | HALVORSON, MARK | 5d |
| 17280380 | HLA SINGLE ALLELE LINES | NEGIN, RUSSELL SCOTT | 21d |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 54d |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 3796 | 1 |
| 1646 | 1 |
| 1627 | 1 |
| 1633 | 1 |
| 1699 | 1 |
| 1622 | 1 |
| 1686 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19355121 | OLIGONUCLEOTIDES FOR PRNP MODULATION | MCLEOD, AFRICA MHAIRIE | 1635 | Other | Non-Final OA | 9d overdue | Pending | Oct 10, 2025 |
| 19197587 | METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS | SAHAND, SANA | 3796 | §101 | Non-Final OA | 32d overdue | Pending | May 02, 2025 |
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | HALVORSON, MARK | 1646 | §112 | Non-Final OA | 5d | Pending | Mar 07, 2025 |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 1627 | §102 | Non-Final OA | 54d | Pending | Sep 01, 2023 |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 1633 | §103 | Final Rejection | 26d | Pending | Aug 09, 2023 |
| 17906115 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING GLUTAMINASE INHIBITOR-SENSITIVE CANCERS | BAUSCH, SARAE L | 1699 | §102 | Non-Final OA | 118d overdue | Pending | Sep 12, 2022 |
| 17776961 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ELENISTE, PIERRE PAUL | 1622 | §102 | Non-Final OA | 127d overdue | Pending | May 13, 2022 |
| 17280380 | HLA SINGLE ALLELE LINES | NEGIN, RUSSELL SCOTT | 1686 | §103 | Non-Final OA | 21d | Pending | Mar 26, 2021 |
| 17029684 | NEXT-GENERATION SEQUENCING ASSAY FOR GENOMIC CHARACTERIZATION AND MINIMAL RESIDUAL DISEASE DETECTION IN THE BONE MARROW, PERIPHERAL BLOOD, AND URINE OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA PATIENTS | JOHANNSEN, DIANA B | 1682 | §103 | Non-Final OA | 54d | Pending | Sep 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial